Background: Studies show titrating insulin in the hospital for 2-4 weeks at diagnosis of type 2 diabetes mellitus (T2DM) can restore production of endogenous insulin to achieve remission. The purpose of the Remission through Early Monitored Insulin Therapy- Duration Month (REMIT-DM) pilot study was to evaluate if individuals with T2DM in an outpatient setting could self-titrate insulin with an innovative titration algorithm using glucose values and trends from a real-time continuous glucose monitor (CGM).

Methods: A diabetes educator trained 10 insulin naïve T2DM participants on use of a basal-bolus multiple daily insulin injection algorithm designed to achieve euglycemia (fasting glucose (FG) < 100 mg/dL, 2-hour (2h) post-prandial glucose (PPG) < 120 mg/dL) during 4 weeks of insulin therapy based on Dexcom G6 real-time CGM values and trends. Primary outcome was participant ability to do algorithm titrations using CGM readings. Secondary outcomes included achievement of goal FG and 2h-PPG, time in days to achievement of goals, CGM time in range (TIR), patient distress via the PAID-5 scale prior to and at completion of the 4-week intervention, and assessment of satisfaction with REMIT-DM experience.

Results: Nine of 10 participants were able to use the self-titration algorithm while 7 achieved goal FG and 8 goal 2h-PPG over 4 weeks of insulin therapy. Mean time to FG and 2h-PPG goals were 9.75 ± 6.01 and 7.11 ± 4.64 days, respectively. Mean CGM TIR during insulin therapy was 80.67 ± 10.7%. Mean PAID-5 scores pre-post use of titration protocol was 8.9 and 7.6, respectively. Scores >8 indicate possible diabetes-related distress. All reported high satisfaction with experience.

Conclusions: Insulin naïve patients were able to follow and self-titrate insulin using real-time CGM values and trends according to an innovative remission insulin algorithm in an outpatient setting. DM-related distress was reduced while all reported satisfaction. Insulin titration at diagnosis warrants further exploration.

Disclosure

S.I. Sobel: None. K. Ruppert: None. P.M. McCarthy: None. L.M. Siminerio: Research Support; Self; Becton, Dickinson and Company. D.A. Rometo: None.

Funding

University of Pittsburgh Clinical and Translational Science Institute

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.